Targeted BIRC2 knockdown, when combined with anti‐PD‐1 therapy, significantly suppressed tumour growth, enhanced CD8+ T cell infiltration, and amplified IFN‐γ and TNF‐α secretion in tumour models. The gene discussed is CD8A; the disease is neoplasm.